Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 19/20 | 0.66 |
| ▸ | ITGA2B | P08514 | 19/20 | 0.66 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.62 |
| ▸ | ITGAM | P11215 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21706030 | 0.86 | ITGB3 (0.75) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7090791 | 0.81 | ITGB3 (0.89) | ITGB3ITGA2BITGB2ITGAMF2 | |
| SCHEMBL21705670 | 0.80 | ITGB3 (0.80) | ITGB3ITGA2BITGB2ITGAMF2 | |
| Roxifiban SCHEMBL24336949 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2B | |
| Roxifiban SCHEMBL344302 | 0.80 | ITGB3 (1.00) | ITGB3ITGA2B | |
| SCHEMBL7372374 | 0.79 | MIF (0.72) | ITGB3ITGA2BITGB2ITGAMF2 | |
| SCHEMBL7373045 | 0.79 | MIF (0.72) | ITGB3ITGA2BITGB2ITGAMF2 | |
| Roxifiban SCHEMBL919675 | 0.78 | ITGB3 (0.95) | ITGB3ITGA2B | |
| SCHEMBL21705409 | 0.77 | ITGB3 (0.66) | ITGB3ITGA2B | |
| SCHEMBL7401821 | 0.77 | ITGB3 (1.00) | ITGB3ITGA2BITGB2ITGAMF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643393-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220081398-A1 | Integrin Antagonists | THE GENERAL HOSPITAL CORPORATION | 2022-03-17 | — | — | US | disclosed |
| WO-2020033724-A1 | INTEGRIN ANTAGONISTS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081398-A1 | Integrin Antagonists | ITGA2B, ITGA2, ITGB2 | ITGB3 9/4885ITGA2B 1/4885ITGB2 3/4885 |
| US-11643393-B2 | Integrin antagonists | ITGA2B, ITGA2, ITGB2 | ITGB3 9/4885ITGA2B 1/4885ITGB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.